FrancophonIA/ELRC3.0 huggingface dataset:
English: In a clinical study, single doses of an oral contraceptive containing ethinyl estradiol and norethindrone were administered on Days 1 through 21 with EMEND, given as a regimen of 125 mg on Day 8 and 80 mg/day on Days 9 and 10 with ondansetron 32 mg intravenously on Day 8 and oral dexamethasone given as 12 mg on Day 8 and 8 mg/day on Days 9, 10, and 11.
Slovenian: V klinični študiji so enkratne odmerke peroralnega kontraceptiva, ki je vseboval etinilestradiol in noretindron, od 1. do 21. dne dajali skupaj z zdravilom EMEND po shemi 125 mg 8. dan in 80 mg/dan 9. in 10. dan, z ondansetronom 32 mg intravensko 8. dan in s peroralnim deksametazonom v obliki 12 mg odmerka 8. dan in 8 mg/dan 9., 10. in 11. dan.
English: Always take this medicine or give this medicine to the child exactly as the doctor, pharmacist or nurse has told you.
Slovenian: Pri jemanju tega zdravila oziroma dajanju tega zdravila otroku natančno upoštevajte navodila zdravnika, farmacevta ali medicinske sestre.
English: What EMEND is and what it is used for What you need to know before you give EMEND How to give EMEND
Slovenian: Kaj je zdravilo EMEND in za kaj ga uporabljamo Kaj morate vedeti, preden boste dali zdravilo EMEND Kako dajati zdravilo EMEND Možni neželeni učinki
English: Dexamethasone: Interaction studies with aprepitant 165 mg and dexamethasone have not been conducted; however, the following study with 200 mg of aprepitant should be considered when using EMEND 165 mg with oral dexamethasone.
Slovenian: Deksametazon: Študije medsebojnega delovanja aprepitanta 165 mg in deksametazona niso bile izvedene, vendar pa je pri uporabi zdravila EMEND 165 mg in peroralnega deksametazona treba upoštevati sledečo študijo z 200 mg aprepitanta.
English: As a moderate inhibitor of CYP3A4, aprepitant can increase plasma concentrations of co-administered active substances that are metabolised through CYP3A4.
Slovenian: Kot zmerni zaviralec CYP3A4 lahko aprepitant zviša plazemske koncentracije sočasno uporabljenih zdravilnih učinkovin, ki se presnavljajo s CYP3A4.
English: Rare side effects (may affect up to 1 in 1,000 people) are: - difficulty thinking, lack of energy, taste disturbance, - sensitivity of the skin to sun, excessive sweating, oily skin, sores on skin, itching rash,
Slovenian: Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov) so: - težave pri razmišljanju, pomanjkanje energije, motnje okušanja, - občutljivost kože na sonce, prekomerno znojenje, mastna koža, razjede po koži, srbeč izpuščaj,
English: Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious or life-threatening reactions.
Slovenian: Aprepitant zavira CYP3A4, zaradi česar bi se lahko zvišale plazemske koncentracije teh zdravilnih učinkovin, kar bi lahko povzročilo resne ali življenjsko nevarne reakcije.
English: Titanium dioxide (E 171) Yellow iron oxide (E 172)
Slovenian: Ovojnica kapsule želatina titanov dioksid (E 171) rumeni železov oksid (E 172)
English: Stop taking EMEND and see a doctor immediately if you or the child notice any of the following side effects, which may be serious, and for which you or the child may need urgent medical treatment: - Hives, rash, itching, difficulty breathing or swallowing (frequency not known, cannot be estimated from the available data); these are signs of an allergic reaction.
Slovenian: Prenehajte jemati zdravilo EMEND in se takoj posvetujte z zdravnikom, če vi ali otrok opazite katerega od naslednjih neželenih učinkov, ki so lahko resni in zaradi katerih boste lahko vi oziroma otrok nujno potrebovali zdravljenje: - koprivnico, izpuščaj, srbenje, težave z dihanjem ali požiranjem (neznana pogostnost, ni je mogoče oceniti iz razpoložljivih podatkov); to so znaki alergijske reakcije.
English: EMEND contains the active substance aprepitant and belongs to a group of medicines called "neurokinin 1 (NK1) receptor antagonists" (antiemetics and antinauseants).
Slovenian: Zdravilo EMEND vsebuje zdravilno učinkovino aprepitant in spada v skupino zdravil, imenovanih "antagonisti receptorjev za nevrokinin 1 (NK1)" (zdravila za preprečevanje bruhanja in slabosti).
English: See the Summary of Product Characteristics (SmPC) for the selected 5-HT3 antagonist for appropriate dosing information.
Slovenian: Za informacije o ustreznem odmerjanju glejte povzetek glavnih značilnosti zdravila (SmPC) za izbrani antagonist 5-HT3.
English: Gastrointestinal disorders abdominal pain upper, bowel sounds abnormal, dry mouth, nausea, stomach discomfort, constipation*, sub-ileus*
Slovenian: Bolezni prebavil bolečine v zgornjem predelu trebuha, nenormalni črevesni zvoki, suha usta, navzea, neugodje v želodcu, zaprtje*, subileus*
English: EMEND, when given as a regimen of 125 mg with dexamethasone co-administered orally as 20 mg on Day 1, and EMEND when given as 80 mg/day with dexamethasone co-administered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate, 2.2-fold on Days 1 and 5.
Slovenian: Pri uporabi po shemi EMEND 125 mg skupaj z deksametazonom 20 mg per os 1. dan ter EMEND 80 mg/dan skupaj z deksametazonom 8 mg per os od drugega do petega dne, je zdravilo EMEND 1. in 5. dan zdravljenja za 2,2-krat povečalo AUC deksametazona, ki je substrat CYP3A4.
English: Each 80 mg capsule contains 80 mg of aprepitant.
Slovenian: Ena 80 mg kapsula vsebuje 80 mg aprepitanta.
English: Do not take more capsules than the doctor recommends.
Slovenian: Če ste vzeli večji odmerek zdravila EMEND, kot bi smeli Ne jemljite večjega števila kapsul, kot vam jih je predpisal zdravnik.
English: Each hard capsule contains 165 mg of aprepitant.
Slovenian: Ena trda kapsula vsebuje 165 mg aprepitanta.
English: Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious reactions.
Slovenian: Aprepitant zavira CYP3A4, zaradi česar bi se lahko zvišale plazemske koncentracije teh zdravilnih učinkovin, kar bi lahko povzročilo resne reakcije.
English: Methylprednisolone: Interaction studies with aprepitant 165 mg and methylprednisolone have not been conducted; however, the following study with the aprepitant 125 mg/80 mg regimen should be considered when using EMEND 165 mg with methylprednisolone.
Slovenian: Metilprednizolon: Študije medsebojnega delovanja aprepitanta 165 mg in metilprednizolona niso bile izvedene, vendar pa je pri uporabi zdravila EMEND 165 mg in metilprednizolona treba upoštevati sledečo študijo z uporabo aprepitanta po shemi 125 mg/80 mg.
English: Each capsule contains 80 mg of sucrose (in the 80 mg capsule).
Slovenian: Pomožna snov z znanim učinkom Ena kapsula vsebuja 80 mg saharoze (v 80 mg kapsuli).
English: These effects were not considered clinically important.
Slovenian: Ti učinki ne veljajo za klinično pomembne.
English: Common side effects (may affect up to 1 in 10 people) are: - constipation, indigestion, - headache, - tiredness, - loss of appetite, - hiccups, - increased amount of liver enzymes in your blood.
Slovenian: Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov) so: - zaprtje, prebavne motnje, - glavobol, - utrujenost, - izguba apetita, - kolcanje, - zvišana vrednost jetrnih encimov v krvi.
English: Before treatment with EMEND, tell the doctor if you or the child have liver disease because the liver is important in breaking down the medicine in the body.
Slovenian: Pred zdravljenjem z zdravilom EMEND obvestite zdravnika, če imate vi ali otrok bolezen jeter, ker jetra sodelujejo pri presnovi zdravila v telesu.
English: EMEND capsules can be taken with or without food.
Slovenian: Zdravilo EMEND se lahko vzame s hrano ali brez hrane.
English: Aluminium blister containing one 165 mg capsule.
Slovenian: Aluminijast pretisni omot, ki vsebuje eno 165 mg kapsulo.
English: Stop giving this medicine and see a doctor straight away if you or the child notice any of the following serious side effects - the child may need urgent medical treatment: - allergic reaction - the signs may include hives, rash, itching, difficulty breathing or swallowing
Slovenian: Prenehajte dajati zdravilo EMEND in takoj obiščite zdravnika, če vi ali vaš otrok opazite katerega od naslednjih neželenih učinkov - otrok bo morda potreboval nujno zdravljenje: - alergijsko reakcijo - med znaki so lahko koprivnica, izpuščaj, srbenje, težave z dihanjem ali požiranjem (ni znano, kako pogosto se to zgodi).
English: Each capsule contains 165 mg of aprepitant.
Slovenian: Ena kapsula vsebuje 165 mg aprepitanta.
English: Choose the oral dispenser based on the dose.
Slovenian: Odmernik izberite glede na velikost odmerka.
English: Aluminium blister containing one 125 mg capsule.
Slovenian: Aluminijast pretisni omot, ki vsebuje eno 125 mg kapsulo.
English: If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Slovenian: Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred začetkom jemanja zdravila pogovorite z zdravnikom.
English: It should be taken into account that some people feel dizzy and sleepy after taking EMEND.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Upoštevati je treba, da nekateri ljudje po zaužitju zdravila EMEND postanejo omotični in zaspani.
English: Each 125 mg capsule contains 125 mg of aprepitant.
Slovenian: Ena 125 mg kapsula vsebuje 125 mg aprepitanta.
English: - increased amount of liver enzymes in your blood.
Slovenian: (pokaže se na preiskavah krvi).
English: • The oral suspension can be kept at room temperature (not above 30°C) for up to 3 hours, prior to administration.
Slovenian: • Peroralno suspenzijo se lahko hrani na sobni temperaturi (do 30 °C) do 3 ure pred uporabo.
English: Alternative non-hormonal back-up methods of contraception should be used during treatment with EMEND and for 2 months following the last dose of EMEND (see sections 4.4 and
Slovenian: Med zdravljenjem z zdravilom EMEND in 2 meseca po zadnjem odmerku zdravila EMEND je treba uporabljati alternativno nehormonsko kontracepcijsko metodo (glejte poglavji 4.4 in 4.5).
English: The aprepitant regimen consisted of aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 and 3 in combination with intravenous ondansetron 32 mg on Day 1 and dexamethasone 12 mg on Day 1 and 8 mg daily on Days 2 through 4.
Slovenian: Režim zdravljenja z aprepitantom je vključeval aprepitant 125 mg 1. dan, 80 mg/dan 2. in 3. dan v kombinaciji z intravenskim ondansetronom 32 mg 1. dan in deksametazonom 12 mg 1. dan ter 8 mg na dan od 2. do 4. dne.
English: These studies did not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Slovenian: Te študije niso pokazale neposrednih ali posrednih škodljivih vplivov na nosečnost, razvoj zarodka/plodu, porod ali postnatalni razvoj (glejte poglavje 5.3).
English: Alternative non-hormonal back-up methods of contraception should be used during treatment with EMEND and for 2 months following the last dose of EMEND (see section 4.5).
Slovenian: Med zdravljenjem z zdravilom EMEND in 2 meseca po zadnjem odmerku zdravila EMEND je treba uporabljati alternativno nehormonsko kontracepcijsko metodo (glejte poglavje 4.5).
English: Each capsule contains 40 mg of aprepitant.
Slovenian: Ena kapsula vsebuje 40 mg aprepitanta.
English: Each hard capsule contains 40 mg of aprepitant.
Slovenian: Ena trda kapsula vsebuje 40 mg aprepitanta.
English: - Use 5 mL oral dispenser if dose is more than 1 mL.
Slovenian: - Če je odmerek večji od 1 ml, uporabite 5-ml odmernik.
English: It should be taken into account that some people may feel dizzy and sleepy after taking EMEND.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Upoštevati je treba, da lahko nekateri ljudje po zaužitju zdravila EMEND postanejo omotični in zaspani.
English: In a third study with intravenous and oral administration of midazolam, EMEND was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, together with ondansetron 32 mg Day 1, dexamethasone 12 mg Day 1 and 8 mg Days 2-4.
Slovenian: V tretji študiji z intravenskim in s peroralnim odmerjanjem midazolama so zdravilo EMEND dajali po shemi 125 mg 1. dan ter 80 mg/dan 2. in 3. dan, skupaj z ondansetronom 32 mg 1. dan in deksametazonom 12 mg 1. dan ter 8 mg 2. do 4. dan.
English: Hydroxypropylcellulose (E 463) Sodium laurilsulfate (E 487) Sucrose
Slovenian: 6.1 Seznam pomožnih snovi hidroksipropilceluloza (E 463) natrijev lavrilsulfat (E 487) saharoza laktoza (brezvodna)
English: Dexamethasone: The usual oral dexamethasone dose should be reduced by approximately 50 % when co-administered with EMEND 125 mg/80 mg regimen.
Slovenian: Deksametazon: Pri sočasnem jemanju z zdravilom EMEND (režim 125 mg/80 mg) je treba običajni peroralni odmerek deksametazona zmanjšati za približno 50 %.
English: Aluminium blister containing two 80 mg capsules.
Slovenian: Aluminijast pretisni omot, ki vsebuje dve 80 mg kapsuli.
English: Gastrointestinal disorders constipation, dyspepsia common eructation, nausea
Slovenian: Bolezni prebavil zaprtje, dispepsija pogosti spahovanje, navzea
English: When to take
Slovenian: Kdaj uporabiti zdravilo
English: Eye disorders miosis, visual acuity reduced uncommon
Slovenian: Očesne bolezni mioza, zmanjšanje ostrine vida občasni
English: 6 Aluminium blisters each containing one 165 mg capsule.
Slovenian: 6 aluminijastih pretisnih omotov, vsak z eno 165 mg kapsulo
English: Respiratory, thoracic and mediastinal disorders hiccups common oropharyngeal pain, sneezing, cough, postnasal drip, throat irritation rare
Slovenian: Bolezni dihal, prsnega koša in mediastinalnega prostora kolcanje pogosti bolečine v ustih in žrelu, kihanje, kašelj, postnazalni izcedek, draženje žrela redki
English: Please refer to the SmPC of co-administered 5-HT3 antagonist medicinal products.
Slovenian: Glejte tudi SmPC za sočasno uporabljeni antagonist 5-HT3.
English: Titanium dioxide (E 171) Red iron oxide (E 172) Yellow iron oxide (E 172)
Slovenian: Ovojnica kapsule (125 mg) želatina titanov dioksid (E 171) rdeči železov oksid (E 172) rumeni železov oksid (E 172)
English: You should not use this medicine during pregnancy unless clearly necessary.
Slovenian: Tega zdravila med nosečnostjo ne smete jemati, razen če je to izrecno potrebno.
English: Infants, toddlers and children (aged 6 months to less than 12 years, and not less than 6 kg) EMEND is given for 3 days as part of a regimen that includes a 5-HT3 antagonist.
Slovenian: Dojenčki, malčki in otroci (stari od 6 mesecev do manj kot 12 let in s telesno maso, ki ni manjša od 6 kg)
English: EMEND contains the active substance aprepitant and belongs to a group of medicines called "neurokinin 1 (NK1) receptor antagonists".
Slovenian: Zdravilo EMEND vsebuje zdravilno učinkovino aprepitant, ki spada v skupino zdravil, imenovanih "antagonisti receptorjev za nevrokinin 1 (NK1)".
English: EMEND 125 mg hard capsules Aprepitant
Slovenian: EMEND 125 mg trde kapsule aprepitant
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING (INCLUDING 1 HARD CAPSULE 125 MG AND 2 HARD CAPUSULES 80 MG)
Slovenian: PODATKI NA PRIMARNI OVOJNINI (Z ENO 125 mg TRDO KAPSULO IN DVEMA 80 mg TRDIMA KAPSULAMA)
English: EMEND contains the active substance ‘aprepitant.'
Slovenian: Zdravilo EMEND vsebuje zdravilno učinkovino aprepitant.
English: A summary of the key study results are shown in Table 4.
Slovenian: Povzetek ključnih rezultatov študije je prikazan v preglednici 4.
English: Each 80 mg hard capsule contains 80 mg of aprepitant.
Slovenian: Ena 80 mg trda kapsula vsebuje 80 mg aprepitanta.
English: COMPOSITE MEASURES
Slovenian: SESTAVLJENI MERILI
English: A summary of the key study results is shown in Table 3.
Slovenian: Povzetek ključnih rezultatov študije je prikazan v preglednici 3.
English: Each capsule contains 125 mg of sucrose (in the 125 mg capsule).
Slovenian: Pomožna snov z znanim učinkom Ena kapsula vsebuje 125 mg saharoze (v 125 mg kapsuli).
English: After reconstitution, 1 mL oral suspension contains 25 mg of aprepitant - The other ingredients are: hydroxypropyl-cellulose (E 463), sodium laurilsulfate (E 487), sucrose and lactose (see section 2 under ‘EMEND contains sucrose and lactose'), red iron oxide (E 172) and sodium stearyl fumarate (E 485).
Slovenian: - Druge sestavine zdravila so: hidroksipropilceluloza (E 463), natrijev lavrilsulfat (E 487), saharoza in laktoza (glejte poglavje 2, "Zdravilo EMEND vsebuje saharozo in laktozo"), rdeči železov oksid (E 172) in natrijev stearilfumarat (E 485)
English: Aluminium blister containing one 40 mg capsule.
Slovenian: Aluminijast pretisni omot, ki vsebuje eno 40 mg kapsulo.
English: Each 125 mg hard capsule contains 125 mg of aprepitant.
Slovenian: Ena 125 mg trda kapsula vsebuje 125 mg aprepitanta.
English: Capsules are opaque with a light blue cap and a white body with “466” and “165 mg” printed radially in black ink on one side of the body and the Merck logo on the other side.
Slovenian: Kapsule so neprozorne; pokrovček je svetlo modre barve, telo je bele barve, na njem sta na eni strani radialno s črnim črnilom natisnjeni oznaki "466" in "165 mg", na drugi strani pa Merckov logotip.
English: Capsules are opaque with a white body and mustard yellow cap with “464” and “40 mg” printed radially in black ink on the body.
Slovenian: Kapsule so neprozorne; telo je bele barve, pokrovček gorčično rumene barve; na telesu kapsule sta radialno s črnim črnilom natisnjeni oznaki "464" in "40 mg".
English: What EMEND is and what it is used for What you need to know before you take EMEND How to take EMEND
Slovenian: Kaj je zdravilo EMEND in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo EMEND Kako jemati zdravilo EMEND Možni neželeni učinki
English: The antiemetic activity of EMEND was evaluated over a 5-day (120 hour) period following the initiation of chemotherapy on Day 1.
Slovenian: Antiemetično delovanje zdravila EMEND so ocenili v 5-dnevnem (120-urnem) obdobju po uvedbi kemoterapije 1. dan. Primarni opazovani dogodek je bil popoln odziv v zapozneli fazi (od 25 do 120 ur po uvedbi kemoterapije) v 1. ciklusu.
English: Uncommon side effects (may affect up to 1 in 100 people) are: - upper stomach pain, bowel sounds abnormal, dry mouth, nausea, stomach discomfort, serious constipation, small bowel not working properly (sub-ileus), - decreased feeling or sensitivity (especially in skin), sensory disturbance, difficulty in speaking, - decrease in pupil size, decrease in sharpness of vision (vision loss), - inability to sleep, - slow heartbeat, - whistling sound while breathing, shortness of breath.
Slovenian: neugodje v želodcu, hudo zaprtje, nepravilno delovanje tankega črevesa (subileus) - zmanjšana občutljivost ali senzitivnost (še posebej v koži), čutilne motnje, težave pri govoru, - zoženje zenice, zmanjšanje ostrine vida (izguba vida), - nespečnost, - počasen srčni utrip, - piskajoče dihanje, kratka sapa.
English: EMEND 165 mg hard capsules Aprepitant
Slovenian: EMEND 165 mg trde kapsule aprepitant
English: Pregnancy and breast-feeding This medicine should not be used during pregnancy and breastfeeding unless clearly necessary.
Slovenian: Tega zdravila se ne sme uporabljati med nosečnostjo in obdobjem dojenja, razen če je izrecno potrebno.
English: EMEND 80 mg hard capsules Aprepitant
Slovenian: EMEND 80 mg trde kapsule aprepitant
English: Before treatment with this medicine, tell your doctor if you have liver disease because your liver is important in breaking down the medicine in your body.
Slovenian: Pred zdravljenjem s tem zdravilom obvestite zdravnika, če imate bolezen jeter, ker jetra sodelujejo pri presnovi zdravila v telesu.
English: EMEND 165 mg hard capsules
Slovenian: EMEND 165 mg trde kapsule
English: How much to take - The doctor will work out the right dose of powder for oral suspension based on the weight of the child. - Do not change the dose or stop treatment without first talking to the doctor, pharmacist or nurse.
Slovenian: Koliko zdravila morate uporabiti - Zdravnik bo določil pravi odmerek praška za peroralno suspenzijo na podlagi otrokove telesne mase.
English: Additional adverse reactions were observed in patients treated with aprepitant for postoperative nausea and vomiting (PONV) and a greater incidence than with ondansetron: abdominal pain upper, bowel sounds abnormal, constipation*, dysarthria, dyspnoea, hypoaesthesia, insomnia, miosis, nausea, sensory disturbance, stomach discomfort, sub-ileus*, visual acuity reduced, wheezing.
Slovenian: Drugi neželeni učinki, ki so bili pri bolnikih, ki so prejemali aprepitant zaradi preprečevanja pooperacijske navzee in bruhanja (PONV - postoperative nausea and vomiting) pogostejši kot pri bolnikih, ki so prejemali ondansetron, so: bolečina v zgornjem predelu trebuha, nenormalni črevesni zvoki, zaprtje*, disartrija, dispneja, hipestezija, nespečnost, mioza, navzea, senzorične motnje, neugodje v želodcu, subileus*, zmanjšanje ostrine vida in piskanje.
English: Use the 1 mL oral dispenser if the dose is 1 mL or less and use the 5 mL oral dispenser if the dose is more than 1 mL.
Slovenian: Če je odmerek 1 ml ali manjši, uporabite 1-ml odmernik.
English: Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered with EMEND 165 mg.
Slovenian: Pri uporabi zdravila EMEND 165 mg svetujemo previdnost pri dajanju varfarina, acenokumarola, tolbutamida, fenitoina in drugih zdravilnih učinkovin, ki se presnavljajo s CYP2C9.
English: The total exposure of orally administered CYP3A4 substrates may increase up to approximately 1.5-fold after a single 40 mg dose of aprepitant; the effect of aprepitant on the plasma concentrations of intravenously administered CYP3A4 substrates is expected to be smaller.
Slovenian: Celokupna izpostavitev peroralno vzetim substratom za CYP3A4 se lahko poveča do približno 1,5-krat med zdravljenjem z enkratnim 40 mg odmerkom aprepitanta.
English: If you feel dizzy or sleepy, you should avoid driving or using machines after taking this medicine (see ‘Possible side effects').
Slovenian: Če ste po zaužitju tega zdravila omotični ali zaspani, se izogibajte vožnji ali upravljanju strojev.
English: Additional adverse reactions were observed in adult patients treated with aprepitant for postoperative nausea and vomiting (PONV) and a greater incidence than with ondansetron: abdominal pain upper, bowel sounds abnormal, constipation*, dysarthria, dyspnoea, hypoaesthesia, insomnia, miosis, nausea, sensory disturbance, stomach discomfort, sub-ileus*, visual acuity reduced, wheezing.
Slovenian: Drugi neželeni učinki, ki so bili pri odraslih bolnikih, ki so prejemali aprepitant zaradi preprečevanja pooperacijske navzee in bruhanja (PONV - postoperative nausea and vomiting) pogostejši kot pri bolnikih, ki so prejemali ondansetron, so: bolečina v zgornjem predelu trebuha, nenormalni črevesni zvoki, zaprtje*, disartrija, dispneja, hipestezija, nespečnost, mioza, navzea, senzorične motnje, neugodje v želodcu, subileus*, zmanjšanje ostrine vida in piskanje.
English: It is important to tell the doctor if you or the child are breast-feeding or are planning to breast-feed before taking this medicine.
Slovenian: Pomembno je, da pred začetkom jemanja tega zdravila poveste zdravniku, če vi ali otrok dojite ali nameravate dojiti.
English: EMEND 125 mg powder for oral suspension aprepitant
Slovenian: EMEND 125 mg prašek za peroralno suspenzijo aprepitant
English: EMEND 40 mg hard capsules Aprepitant
Slovenian: EMEND 40 mg trde kapsule aprepitant
English: Renal and urinary disorders dysuria uncommon pollakiuria rare
Slovenian: Bolezni sečil disurija občasni polakisurija redki
English: The following adverse reactions were observed in PONV studies in adults treated with aprepitant at a greater incidence than with ondansetron or in postmarketing use:
Slovenian: Spodaj so navedeni neželeni učinki, ki so jih v študijah PONV pri odraslih, zdravljenih z aprepitantom, opazili pogosteje kot pri odraslih, zdravljenih z ondansetronom, in neželeni učinki iz obdobja trženja.
English: How to take EMEND
Slovenian: Kako jemati zdravilo EMEND